Globus Medical (NYSE:GMED) Given New $100.00 Price Target at Wells Fargo & Company

Globus Medical (NYSE:GMED) had its price objective hoisted by Wells Fargo & Company from $99.00 to $100.00 in a research report released on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical device company’s stock.

Several other brokerages also recently commented on GMED. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a report on Friday. UBS Group started coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Truist Financial reduced their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Finally, Needham & Company LLC decreased their target price on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.92.

Globus Medical Stock Down 13.2%

Shares of NYSE GMED traded down $10.77 during trading on Friday, hitting $70.67. 9,272,194 shares of the company traded hands, compared to its average volume of 1,321,886. The firm has a market capitalization of $9.49 billion, a P/E ratio of 17.36, a P/E/G ratio of 1.28 and a beta of 0.98. The company has a 50-day moving average price of $77.20 and a 200-day moving average price of $83.18. Globus Medical has a 1 year low of $70.39 and a 1 year high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.03. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. During the same quarter in the prior year, the business earned $1.18 earnings per share. The business’s quarterly revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Research analysts predict that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Buying and Selling at Globus Medical

In related news, Director Ann D. Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the sale, the director directly owned 35,384 shares in the company, valued at $3,007,640. This trade represents a 12.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 60,000 shares of company stock valued at $4,838,400 in the last ninety days. Company insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC raised its position in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares in the last quarter. Sculptor Capital LP boosted its position in shares of Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Globus Medical by 14.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock worth $133,731,000 after purchasing an additional 225,534 shares during the last quarter. Finally, Boston Trust Walden Corp grew its position in Globus Medical by 4.4% in the third quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock worth $123,071,000 after buying an additional 69,782 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.